Clayton, Dubilier & Rice in its $205 million acquisition of Cynosure from Hologic.
Debevoise & Plimpton LLP is advising Clayton, Dubilier & Rice (“CD&R”), a private investment firm, in its acquisition of Cynosure, LLC, a market-leading medical aesthetics technology company. Under the terms of the agreement, approximately 825 employees will transfer with the Cynosure business. The transaction is expected to close in January 2020, subject to regulatory approvals and other customary conditions. UBS has committed to provide debt financing as part of the transaction and is acting as financial advisor to CD&R. This carveout style transaction positions Cynosure for accelerated growth under new ownership and is expected to have an immaterial impact on Hologic Inc.’s (Cynosure’s parent company) revenue growth rate, while increasing non-GAAP gross and operating margin as a percentage of revenue. For more information, please see CD&R’s release. Read More>